Embecta Reaffirms 2025 Outlook With Up to $1.09B Revenue, Unveils Long-Term Plan to Cut $500M Debt

Author: Benzinga Newsdesk | May 22, 2025 05:35am

Embecta Corp. ("embecta"; "The Company") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present its long range financial plan ("LRP").

"Our Investor Day will provide a comprehensive view of our roadmap for transitioning embecta to growth. We look forward to sharing how we are positioning embecta for long-term success in an evolving healthcare landscape," said Dev Kurdikar, President and Chief Executive Officer. "Today, we reiterate our commitment to maintaining our leadership in insulin injection while outlining our long term vision to transform embecta into a more broad-based medical supplies company, paving the way toward a life unlimited for all."

Strategic Priorities

embecta's core insulin injection business has long provided a stable, recurring, and geographically diversified revenue base with an attractive margin profile. Following a successful three-year effort to establish embecta as an independent, standalone organization, the Company is currently focused on three strategic priorities aimed at positioning embecta for sustainable, long-term success:

• Strengthening the core business, which includes executing a seamless brand transition to ensure embecta's identity resonates globally while maintaining the trust of customers. At the same time, the company is continuing to identify opportunities within its core portfolio that bolster its leadership position in injection devices.
  
  
  
   
• Expanding the Company's product portfolio through the introduction of products that leverage embecta's expertise in high-volume manufacturing and the strength of its global commercial channel.
  
  
  
   
• Increasing financial flexibility by generating cost savings through operational efficiencies and prioritizing debt reduction, thereby enhancing the Company's financial agility and ability to make future investments.
  
   

Fiscal Year 2025 Financial Guidance

embecta today reaffirmed its fiscal year 2025 guidance, originally provided in conjunction with its second quarter of fiscal 2025 financial results announced on May 9, 2025.

Dollars in millions, except percentages and per share data
Reported Revenues	$1,073 - $1,090
Reported Revenue Growth (%)	(4.4)% - (2.9)%
Impact of F/X (%)	(0.8%)
Impact of Italian Payback Measure (1) (%)	0.4%
Adjusted Constant Currency Revenue Growth (%)	(4.0)% - (2.5)%
Adjusted Gross Margin (%)	62.75% - 63.75%
Adjusted Operating Margin (%)	29.75% - 30.75%
Adjusted Earnings per Diluted Share	$2.70 - $2.90
Adjusted EBITDA Margin (%)	36.25% - 37.25%

(1) Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015 recorded in Revenues.

 

Long Range Financial Plan

embecta today announced its long range financial plan for fiscal 2025 through fiscal 2028.

Over this period, the Company expects to:

• Maintain a flattish constant currency revenue CAGR
• Achieve an adjusted operating margin of approximately 28% to 30%
• Generate approximately $600 million of cumulative free cash flow(1)
• Repay between $450 million and $500 million of debt

Posted In: EMBC